Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
EDV vs IBB: how they differ
EDV and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
Vanguard Extended Duration Treasury Index Fund and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, EDV and IBB hold 0% of their money in the same securities at the same weight.
| Only in EDV | Only in IBB |
|---|---|
| United States Treasury Strip Coupon 1.82% | Vertex Pharmaceuticals, Inc. 8.09% |
| United States Treasury Strip Principal 1.76% | Amgen, Inc. 7.84% |
| United States Treasury Strip Coupon 1.72% | Gilead Sciences, Inc. 6.85% |
| United States Treasury Strip Principal 1.70% | Regeneron Pharmaceuticals, Inc. 4.91% |
| United States Treasury Strip Coupon 1.68% | Argenx SE 3.76% |
| United States Treasury Strip Principal 1.65% | Alnylam Pharmaceuticals, Inc. 3.12% |
| United States Treasury Strip Coupon 1.60% | Natera, Inc. 2.89% |
| United States Treasury Strip Principal 1.57% | Revolution Medicines, Inc. 2.78% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| EDV Vanguard Extended Duration Treasury Index Fund | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | iShares |
| What it is | Extended Duration Treasury | Biotechnology |
| Total return, 1 year | −10.8% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −28.3 pts | +24.0 pts |
| Expense ratio | 0.05% | 0.44% |
| Holdings | 82 | 248 |
EDV in plain words
EDV is a bond fund tracking the Extended Duration Treasury. Over the year to Sep 11, 2026 it returned −10.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.05% a year. It sat 57.3% below its high of Mar 9, 2020 on Sep 11, 2026.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, EDV or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, EDV returned −10.8% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, EDV or IBB?
- EDV charges 0.05% a year and IBB charges 0.44%, so EDV is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, EDV against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/EDV-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources